Delivery Order SPE2DB25D3008-SPE2DB25FRDHV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) under a firm fixed-price contract valued at $1,385.52, with an ultimate completion date of October 8, 2025. This non-set-aside award reflects competitive procurement through open competition and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units), with an ultimate completion date of August 25, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,156.56 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count packages) on September 22, 2025, with completion targeted for October 14, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $1,385.52 delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) under a firm fixed-price contract. The award was made on August 6, 2025, with an ultimate completion date of August 27, 2025, and does not utilize a set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order represents a child contract under the...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $4,156.56 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit dose packages) on June 2, 2025, with completion targeted for June 24, 2025. This firm fixed-price, non-set-aside delivery order represents a competitive award to the pharmaceutical distributor's Conshohocken, Pennsylvania location. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (SPE2DX)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units, with a ceiling value of $1,385.52. This competitive award, utilizing firm fixed pricing, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 30-unit supplies of ORGOVYX 120 mg tablets, valued at $1,385.52 with a firm fixed price structure. This non-competitive delivery order was awarded on August 12, 2025, with an ultimate completion date of September 3, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under a larger indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,156.56 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30 units per package. This is a firm fixed price delivery order with no set-aside designation, issued on August 28, 2025, with an ultimate completion date of September 19, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30-count units, with a contract ceiling value of $1,385.52 and a completion date of October 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) with a ceiling value of $4,156.56 under a firm fixed-price contract. This non-competitive delivery order, issued on June 2, 2025, represents a single pharmaceutical procurement to be fulfilled by June 24, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB25D3008Indefinite Delivery Contract
- SPE2DB25D3008-SPE2DB25FRDHVDelivery Order
The Defense Logistics Agency awarded a $1,385.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) on September 22, 2025, with an ultimate completion date of October 14, 2025. This non-competitive delivery order leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the primary vehicle for pharmaceutical supply to military and federal healthcare systems. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen consistently fulfills delivery orders for a comprehensive range of brand-name and generic medications across multiple therapeutic domains, including specialty pharmaceuticals, vaccines, and medical supplies. ORGOVYX is a prescription medication used in hormone therapy, demonstrating the company's role in supplying specialized medical commodities to support Defense Health Agency, U.S. Coast Guard, and broader military healthcare operations. The company's extensive portfolio of federal contracts and significant prime vendor status position it as a key supplier within the DLA's global pharmaceutical support infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 9/22/25 |